CAR-T 细胞治疗前基于苯达莫司汀的淋巴细胞清除：一项系统综述

Bendamustine-based lymphodepletion prior to CAR T-cell therapy: a systematic review.

套细胞淋巴瘤转化为 CD19 阴性经典型霍奇金淋巴瘤：CD19 CAR-T 细胞治疗逃逸的新机制

Mantle cell lymphoma transformation to CD19-negative classic Hodgkin lymphoma as a novel mechanism of escape from CD19 chimeric antigen receptor T cel

成人 CD30 CAR-T 细胞治疗后的感染并发症

Infectious Complications Following CD30 Chimeric Antigen Receptor T-cell Therapy in Adults.

SOHO 最新进展与后续问题 | 原发性纵隔 B 细胞淋巴瘤治疗的最新进展

SOHO State of the Art Updates and Next Questions | Latest Advances in the Management of Primary Mediastinal B-Cell Lymphoma.

淋巴瘤中嵌合抗原受体疗法的新型与多重靶点

Novel and multiple targets for chimeric antigen receptor-based therapies in lymphoma.

基于 T 细胞亚群列线图的复发/难治性 B 细胞非霍奇金淋巴瘤患者 CAR-T 反应预测模型

A CAR-T response prediction model for r/r B-NHL patients based on a T cell subset nomogram.

研究发现，Tc 中 Tcm 与 Tn 的比值能够预测 CD19 CAR-T 细胞在复发/难治性 B-NHL 中的治疗反应。

淋巴瘤的 CAR-T 细胞治疗：新场景与未来方向

Chimeric Antigen Receptor-T Cell Therapy for Lymphoma: New Settings and Future Directions.

经典型霍奇金淋巴瘤的 CAR-T 细胞治疗

CAR-T Cell Therapy for Classical Hodgkin Lymphoma.

霍奇金淋巴瘤的遗传学病变与靶向治疗

Genetic lesions and targeted therapy in Hodgkin lymphoma.

儿童和青少年癌症患者 CAR-T 细胞药物研发儿科战略论坛：ACCELERATE 与欧洲药品管理局合作、美国食品药品监督管理局参与

Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE i